You are here: Home » News-CM » Companies » News
Business Standard

Alembic Pharmaceuticals receives USFDA approval for ANDA Bimatoprost Ophthalmic Solution

Capital Market 

has received approval from the (USFDA) for its Abbreviated New Drug Application (ANDA) Solution, 0.03%.

The approved is therapeutically equivalent to the reference listed drug (RLD), Lumigan, 0.03% of Sales, (Allergan). Solution, 0.03% is indicated for the reduction of elevated in patients with open angle or

Solution, 0.03% have an estimated market size of US$ 76 million for twelve months ending December 2018 according to IQVIA.

Alembic now has a total of 90 approvals (78 final approvals and 12 tentative approvals) from USFDA.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, April 15 2019. 10:25 IST